Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 1999 Aug;91(8 Suppl):26S–39S.

New treatments for asthma: the role of leukotriene modifier agents.

D J Valacer 1
PMCID: PMC2608482  PMID: 12653390

Abstract

The three leukotriene (LT) modifiers approved for use in the United States, zileuton, zafirlukast, and montelukast, are the first new class of therapeutic agents to be introduced in 20 years for the treatment of asthma. These agents are referred to as leukotriene modifiers and have clearly demonstrated the ability to ameliorate bronchoconstriction and indices of airway edema and abnormal mucus production as observed in clinical trials. These agents have been shown to improve airflow, reduce the need for an inhaled bronchodilator, and improve nocturnal awakenings and asthma symptom scores appreciably. When combined with inhaled corticosteroid therapy, they may either provide additional improvement in efficacy or permit the reduction of the dose of inhaled corticosteroid necessary for effective therapy. Physicians should be familiar with these agents and consider them for use in their practice, in conjunction with current asthma management guidelines.

Full text

PDF
26S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Awni W. M., Hussein Z., Granneman G. R., Patterson K. J., Dubé L. M., Cavanaugh J. H. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokinet. 1995;29 (Suppl 2):67–76. doi: 10.2165/00003088-199500292-00010. [DOI] [PubMed] [Google Scholar]
  2. Calhoun W. J., Lavins B. J., Minkwitz M. C., Evans R., Gleich G. J., Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1381–1389. doi: 10.1164/ajrccm.157.5.9609014. [DOI] [PubMed] [Google Scholar]
  3. Calhoun W. J., Lavins B. J., Minkwitz M. C., Evans R., Gleich G. J., Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1381–1389. doi: 10.1164/ajrccm.157.5.9609014. [DOI] [PubMed] [Google Scholar]
  4. Calhoun WJ. Summary of clinical trials with zafirlukast . Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):S238–S246. [PubMed] [Google Scholar]
  5. Dworski R., Fitzgerald G. A., Oates J. A., Sheller J. R. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med. 1994 Apr;149(4 Pt 1):953–959. doi: 10.1164/ajrccm.149.4.8143061. [DOI] [PubMed] [Google Scholar]
  6. Finnerty J. P., Wood-Baker R., Thomson H., Holgate S. T. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):746–749. doi: 10.1164/ajrccm/145.4_Pt_1.746. [DOI] [PubMed] [Google Scholar]
  7. Fish J. E., Kemp J. P., Lockey R. F., Glass M., Hanby L. A., Bonuccelli C. M. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clin Ther. 1997 Jul-Aug;19(4):675–690. doi: 10.1016/s0149-2918(97)80092-6. [DOI] [PubMed] [Google Scholar]
  8. Fish J. E., Kemp J. P., Lockey R. F., Glass M., Hanby L. A., Bonuccelli C. M. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clin Ther. 1997 Jul-Aug;19(4):675–690. doi: 10.1016/s0149-2918(97)80092-6. [DOI] [PubMed] [Google Scholar]
  9. Granneman G. R., Braeckman R. A., Locke C. S., Cavanaugh J. H., Dubé L. M., Awni W. M. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet. 1995;29 (Suppl 2):77–83. doi: 10.2165/00003088-199500292-00011. [DOI] [PubMed] [Google Scholar]
  10. Henderson W. R., Jr Role of leukotrienes in asthma. Ann Allergy. 1994 Mar;72(3):272–278. [PubMed] [Google Scholar]
  11. Holgate S. T., Bradding P., Sampson A. P. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol. 1996 Jul;98(1):1–13. doi: 10.1016/s0091-6749(96)70220-8. [DOI] [PubMed] [Google Scholar]
  12. Holgate S. T., Bradding P., Sampson A. P. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol. 1996 Jul;98(1):1–13. doi: 10.1016/s0091-6749(96)70220-8. [DOI] [PubMed] [Google Scholar]
  13. Israel E., Cohn J., Dubé L., Drazen J. M. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA. 1996 Mar 27;275(12):931–936. [PubMed] [Google Scholar]
  14. Kane G. C., Pollice M., Kim C. J., Cohn J., Dworski R. T., Murray J. J., Sheller J. R., Fish J. E., Peters S. P. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol. 1996 Feb;97(2):646–654. doi: 10.1016/s0091-6749(96)70310-x. [DOI] [PubMed] [Google Scholar]
  15. Kemp J. P., Dockhorn R. J., Shapiro G. G., Nguyen H. H., Reiss T. F., Seidenberg B. C., Knorr B. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr. 1998 Sep;133(3):424–428. doi: 10.1016/s0022-3476(98)70281-1. [DOI] [PubMed] [Google Scholar]
  16. Kikawa Y., Miyanomae T., Inoue Y., Saito M., Nakai A., Shigematsu Y., Hosoi S., Sudo M. Urinary leukotriene E4 after exercise challenge in children with asthma. J Allergy Clin Immunol. 1992 Jun;89(6):1111–1119. doi: 10.1016/0091-6749(92)90294-c. [DOI] [PubMed] [Google Scholar]
  17. Knorr B., Matz J., Bernstein J. A., Nguyen H., Seidenberg B. C., Reiss T. F., Becker A. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA. 1998 Apr 15;279(15):1181–1186. doi: 10.1001/jama.279.15.1181. [DOI] [PubMed] [Google Scholar]
  18. Leff J. A., Busse W. W., Pearlman D., Bronsky E. A., Kemp J., Hendeles L., Dockhorn R., Kundu S., Zhang J., Seidenberg B. C. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998 Jul 16;339(3):147–152. doi: 10.1056/NEJM199807163390302. [DOI] [PubMed] [Google Scholar]
  19. Leff J. A., Busse W. W., Pearlman D., Bronsky E. A., Kemp J., Hendeles L., Dockhorn R., Kundu S., Zhang J., Seidenberg B. C. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998 Jul 16;339(3):147–152. doi: 10.1056/NEJM199807163390302. [DOI] [PubMed] [Google Scholar]
  20. Liu M. C., Dubé L. M., Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol. 1996 Nov;98(5 Pt 1):859–871. doi: 10.1016/s0091-6749(96)80002-9. [DOI] [PubMed] [Google Scholar]
  21. Malmstrom K., Rodriguez-Gomez G., Guerra J., Villaran C., Piñeiro A., Wei L. X., Seidenberg B. C., Reiss T. F. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med. 1999 Mar 16;130(6):487–495. doi: 10.7326/0003-4819-130-6-199903160-00005. [DOI] [PubMed] [Google Scholar]
  22. Marom Z., Shelhamer J. H., Bach M. K., Morton D. R., Kaliner M. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis. 1982 Sep;126(3):449–451. doi: 10.1164/arrd.1982.126.3.449. [DOI] [PubMed] [Google Scholar]
  23. Meltzer S. S., Hasday J. D., Cohn J., Bleecker E. R. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med. 1996 Mar;153(3):931–935. doi: 10.1164/ajrccm.153.3.8630575. [DOI] [PubMed] [Google Scholar]
  24. Reiss T. F., Chervinsky P., Dockhorn R. J., Shingo S., Seidenberg B., Edwards T. B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med. 1998 Jun 8;158(11):1213–1220. doi: 10.1001/archinte.158.11.1213. [DOI] [PubMed] [Google Scholar]
  25. Reiss T. F., Chervinsky P., Dockhorn R. J., Shingo S., Seidenberg B., Edwards T. B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med. 1998 Jun 8;158(11):1213–1220. doi: 10.1001/archinte.158.11.1213. [DOI] [PubMed] [Google Scholar]
  26. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983 May 6;220(4597):568–575. doi: 10.1126/science.6301011. [DOI] [PubMed] [Google Scholar]
  27. Spector S. L., Smith L. J., Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med. 1994 Sep;150(3):618–623. doi: 10.1164/ajrccm.150.3.8087328. [DOI] [PubMed] [Google Scholar]
  28. Suissa S., Dennis R., Ernst P., Sheehy O., Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997 Feb 1;126(3):177–183. doi: 10.7326/0003-4819-126-3-199702010-00001. [DOI] [PubMed] [Google Scholar]
  29. Taylor I. K., O'Shaughnessy K. M., Fuller R. W., Dollery C. T. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991 Mar 23;337(8743):690–694. doi: 10.1016/0140-6736(91)90277-v. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES